Propel Bio Partners
Overview
Propel Bio Partners is a venture capital and equity investment firm that invests in and supports life science companies at various stages. The firm focuses on companies developing disruptive therapies and technologies to advance human health, with a portfolio spanning private and public biotech and pharma companies from clinical development to commercialization. Co-founded by Richard Kayne and Dr. Leen Kawas, the firm also emphasizes investing in companies that promote diversity and inclusive research.
Portfolio Companies
3
Website
propelbio.comInvestments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Persephone Biosciences | Jul 2022 | Seed | Lead |
| Inherent Biosciences, Inc. | Sep 2022 | Series A | Lead |
| EIT Pharma | Aug 2026 | Series A | Lead |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Propel Bio Partners based?
Propel Bio Partners is headquartered in Los Angeles, California, United States.
When was Propel Bio Partners founded?
Founding year information for Propel Bio Partners is not publicly available.
How many portfolio companies does Propel Bio Partners have?
Propel Bio Partners has 3 portfolio companies in Caplight's dataset.
What are some companies in Propel Bio Partners's portfolio?
Portfolio companies visible on Caplight include Persephone Biosciences, Inherent Biosciences, Inc., EIT Pharma.
What was Propel Bio Partners's most recent investment shown here?
Propel Bio Partners's most recent investment in this portfolio sample was in EIT Pharma in 2026.
What sectors does Propel Bio Partners focus on?
Propel Bio Partners focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, AI, Data & Cloud Infrastructure.
What company stages does Propel Bio Partners focus on?
Propel Bio Partners typically invests at the Early stage.